Status:
COMPLETED
Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
Lead Sponsor:
Rutgers, The State University of New Jersey
Collaborating Sponsors:
Rutgers Cancer Institute of New Jersey
National Cancer Institute (NCI)
Conditions:
Metastatic Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this research study is to look at the effectiveness of a combination of doxil, carboplatin and bevacizumab on metastatic breast cancer. The type of breast cancer being studied is negati...
Eligibility Criteria
Inclusion
- Women with previously untreated metastatic breast cancer, ER/PR/HER2/neu negative.
- Age \>= 18
- ECOG performance status \<= 2
- Normal organ and marrow function
- Normal cardiac function as evidenced by LVEF within institutional normal limits
Exclusion
- History of hypersensitivity reactions to doxil or bevacizumab
- Myocardial infarct or unstable angina within 6 months before enrollment
- Prior anthracycline dose exceeding 360 mg/m2 for doxorubicin (including DOXIL) or 720 mg/m2 for epirubicin.
- Proteinuria
Key Trial Info
Start Date :
May 16 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 25 2015
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT00608972
Start Date
May 16 2008
End Date
September 25 2015
Last Update
February 8 2023
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Cooper Hospital/University Medical Center
Camden, New Jersey, United States, 08103
2
Cancer Institute of New Jersey at Hamilton
Hamilton, New Jersey, United States, 08690
3
Morristown Medical Center
Morristown, New Jersey, United States, 07960
4
Jersey Shore University Medical Center
Neptune City, New Jersey, United States, 07753